NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free MLYS Stock Alerts $14.27 -0.38 (-2.59%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$13.76▼$15.0050-Day Range$10.75▼$15.3452-Week Range$5.85▼$17.70Volume189,561 shsAverage Volume164,103 shsMarket Capitalization$708.23 millionP/E RatioN/ADividend YieldN/APrice Target$33.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside134.8% Upside$33.50 Price TargetShort InterestBearish3.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 7 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.44) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector440th out of 915 stocksPharmaceutical Preparations Industry200th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.77% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 2.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 1.7 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Mineralys Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.44) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -7.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -7.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThings Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.This could be your solution. About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesMay 9, 2024 | msn.comMineralys Therapeutics GAAP EPS of -$0.70 misses by $0.03May 9, 2024 | globenewswire.comMineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.May 8, 2024 | americanbankingnews.comMineralys Therapeutics (MLYS) Set to Announce Quarterly Earnings on ThursdayMay 6, 2024 | globenewswire.comMineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceMay 3, 2024 | msn.comMineralys Therapeutics to Unveil First Quarter Financial ResultsMay 2, 2024 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024April 2, 2024 | msn.comGoldman starts Mineralys at buy, cites upcoming drug dataMay 10, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsMarch 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesFebruary 9, 2024 | seekingalpha.comMineralys: 2nd Half 2024 Hypertension Data ReadoutFebruary 9, 2024 | bizjournals.comMineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressureFebruary 9, 2024 | msn.comMineralys Therapeutics Equity Sales: Investor Impact ReportSee More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/09/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$33.50 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.48% Return on Assets-25.52% Debt Debt-to-Equity RatioN/A Current Ratio23.76 Quick Ratio23.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book2.41Miscellaneous Outstanding Shares49,630,000Free Float33,134,000Market Cap$703.26 million OptionableOptionable Beta2.05 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Comp: $69.33kMr. Jon Congleton (Age 61)CEO & Director Comp: $775.77kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $655.58kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsAnaptysBioNASDAQ:ANABDianthus TherapeuticsNASDAQ:DNTHWave Life SciencesNASDAQ:WVENurix TherapeuticsNASDAQ:NRIXNuvation BioNYSE:NUVBView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 3,181 shares on 4/29/2024Ownership: 0.016%PNC Financial Services Group Inc.Bought 4,099 shares on 3/22/2024Ownership: 0.010%Catalys Pacific LLCBought 9,194,579 shares on 2/14/2024Ownership: 22.371%Sectoral Asset Management Inc.Sold 235,153 shares on 2/14/2024Ownership: 1.473%Pale Fire Capital SEBought 34,743 shares on 2/14/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1 year price targets for Mineralys Therapeutics' shares. Their MLYS share price targets range from $30.00 to $37.00. On average, they anticipate the company's share price to reach $33.50 in the next year. This suggests a possible upside of 134.8% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2024? Mineralys Therapeutics' stock was trading at $8.60 at the beginning of the year. Since then, MLYS shares have increased by 65.9% and is now trading at $14.27. View the best growth stocks for 2024 here. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.24. What ETFs hold Mineralys Therapeutics' stock? ETFs with the largest weight of Mineralys Therapeutics (NASDAQ:MLYS) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) and When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, LP and Samsara Biocapital Gp, Llc. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.